| Literature DB >> 26594117 |
Lateef M Khan1, Sameer E Al-Harthi1, Huda M Alkreathy1, Abdel-Moneim M Osman2, Ahmed S Ali1.
Abstract
OBJECTIVE: To determine the PPVs of selected ten medication antidote signals in recognizing potential ADRs and comparison of their sensitivity with manual chart analysis, and voluntary reporting recognizing the same ADRs.Entities:
Keywords: Adverse drug reactions; Electronic medical record; Medication antidote signals; Positive predictive value
Year: 2014 PMID: 26594117 PMCID: PMC4605900 DOI: 10.1016/j.jsps.2014.10.003
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
List of drugs selected for the study as medication antidotes administered by parenteral route except Loperamide.
| Medication antidotes | Signals |
|---|---|
| Dextrose 50% | Hypoglycemia |
| Metoclopramide | Nausea and vomiting in relation to drug use |
| Methylprednisolone | Hypersensitivity skin reaction |
| Phytonadione | Bleeding with warfarin |
| Protamine | Heparin induced toxicity |
| Sodium Polystyrene | Drug induced hyperkalemia |
| Potassium Chloride | Drug induced hypokalemia |
| Promethazine | Hypersensitivity skin reaction |
| Acetylcysteine | Paracetamol toxicity |
| Loperamide | Antimicrobial induced diarrhea |
Figure 1Demographic data of 7589 patients recipient of specific antidote medications.
Depicting sensitivity, specificity and positive predictive values of ten medication antidote signals.
| Antidote signals | Antidote signals confirmed as ADRs | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) |
|---|---|---|---|---|
| Acetylcysteine | 03 | 100 (30.5–100) | 99.1 (98.3–99.6) | 0.33 (0.18–0.62) |
| Dextrose 50% | 19 | 82.6 (61.2–94.9) | 94.1 (92.6–95.5) | 0.30 (0.16–0.54) |
| Methylprednisolone | 27 | 90 (73.4–97.8) | 91.4 (89.6–92.9) | 0.28 (0.11–0.43) |
| Metoclopramide | 62 | 93.9 (85.2–98.3) | 98.2 (97.2–98.9) | 0.29 (0.13–0.47) |
| Phytonadione | 25 | 71.4 (53.7–85.3) | 92.1 (90 93.6) | 0.28 ((0.11–0.43) |
| Potassium Chloride | 89 | 100 (95.9–100) | 77.4 (75.1–79.6) | 0.29 (0.13–0.47) |
| Promethazine | 21 | 95.5 (77.1–99.2) | 93.6 (91.9–94.9) | 0.30 (0.16–0.54) |
| Protamine | 03 | 100 (30.5–100) | 99 (98.3–99.6) | 0.33 (0.18–0.62) |
| Sodium Polystyrene | 50 | 94.3 (84.3–98.7) | 86.1 (83.9–87.9) | 0.30 (0.16–0.54) |
| Loperamide | 03 | 60 (15.4–93.5) | 99 (98.2–99.5) | 0.30 (0.16–0.54) |
| Average (SD) | 30.2 (28.5) | 93 (89.7–95.5) | 58.8 (56.5–61.2) | 0.29 (0.16–0.54) |
Comparison of the sensitivities of common methods of ADR detection with ADRs detected by antidote signals.
| Antidote signals | Antidote signals confirmed as ADRs | Voluntarily reported ADRs (%) | Obvious ADRs recognized from progress notes of the patients (%) | |
|---|---|---|---|---|
| Dextrose 50% | 19 | 0 (0) | 04 (21) | 0.0001 |
| Metoclopramide HCl | 62 | 04 (6) | 07 (11) | 0.0001 |
| Methylprednisolone | 27 | 03 (11) | 06 (22) | 0.0017 |
| Phytonadione | 25 | 10 (40) | 04 (16) | 1.0000 |
| Protamine | 03 | 0 (0) | 01 (33) | 0.2500 |
| Sodium Polystyrene | 50 | 03 (6) | 15 (30) | 0.0001 |
| Potassium Chloride | 89 | 0 (0) | 07 (8) | 0.0001 |
| Promethazine | 21 | 01 (5) | 07 (33) | 0.0001 |
| Acetylcysteine | 03 | 0 (0) | 01 (33) | 0.2500 |
| Loperamide | 03 | 02 (67) | 0 (0) | 0.1165 |
| Total ADRs | 302 | 23 (8) | 52 (17) | 0.0001 |
ADRs confirmed using the agreement of Naranjo’s scale causality assessment tool.
P-value was determined by Fischer exact test, within the group analysis of ADRs detected by medication antidote signals, review charts and voluntarily reported.
Very significant.
Extremely significant.
Not statistically significant.
Figure 2Bar diagram depicting the preventable ADRs and severity of ADRs detected by antidote medication signals confirmed as ADRs.